title: Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.
abstract: Although oral iron is the initial treatment approach for iron deficiency anemia (IDA), some patients fail to respond to or cannot tolerate oral iron. This double-blind safety and efficacy study of the intravenous (IV) iron, ferumoxytol, randomized patients with a history of unsatisfactory oral iron therapy, or in whom oral iron could not be used, to ferumoxytol (n = 609) or placebo (n = 203). The proportion of patients achieving the primary endpoint (hemoglobin increase ≥2.0 g/dL at Week 5) was 81.1% with ferumoxytol versus 5.5% with placebo (P < 0.0001). The mean increase in hemoglobin from Baseline to Week 5, a secondary endpoint (also the alternative preplanned primary efficacy endpoint for other health authorities), was 2.7 versus 0.1 g/dL (P < 0.0001). Achievement of a hemoglobin ≥12 g/dL, time to a hemoglobin increase ≥2.0 g/dL, and improvement in the Functional Assessment of Chronic Illness Therapy Fatigue score also significantly favored ferumoxytol over placebo at Week 5 (P < 0.0001). Ferumoxytol treatment-emergent adverse events were mainly mild to moderate. Ferumoxytol was effective and well tolerated in patients with IDA of any underlying cause in whom oral iron was ineffective or could not be used. This trial was registered at www.clinicaltrials.gov as #NCT01114139.
authors: The University of Texas MD Anderson Cancer Center, Houston, Texas.
authors: Saroj
authors: S
authors: Vadhan-Raj
authors: William
authors: W
authors: Strauss
authors: David
authors: D
authors: Ford
authors: Kristine
authors: K
authors: Bernard
authors: Ralph
authors: R
authors: Boccia
authors: Joe
authors: J
authors: Li
authors: Lee F
authors: LF
authors: Allen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D005260:Female; D052203:Ferrosoferric Oxide / Q000008:administration & dosage* / Q000009:adverse effects; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D007501:Iron; D052203:Ferrosoferric Oxide
references: Fam Pract. 2005 Feb;22(1):58-61
references: 15644385
references: Am J Med. 2000 Jul;109(1):27-32
references: 10936475
references: Age Ageing. 1981 Feb;10(1):40-3
references: 6971043
references: Eur J Cancer. 2003 Feb;39(3):335-45
references: 12565986
references: Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93
references: 19176796
references: Curr Med Res Opin. 2007 Apr;23(4):731-9
references: 17407629
references: Qual Life Res. 2000;9(5):491-7
references: 11190004
references: Eur J Gastroenterol Hepatol. 2012 Feb;24(2):109-16
references: 22157204
references: Kidney Int. 2005 Oct;68(4):1801-7
references: 16164657
references: Drugs. 2012 Oct 22;72(15):2013-22
references: 22994536
references: J Nutr. 2001 Feb;131(2S-2):697S-700S; discussion 700S-701S
references: 11160600
references: Ann Oncol. 2004 Jun;15(6):979-86
references: 15151958
references: J Pain Symptom Manage. 2002 Dec;24(6):547-61
references: 12551804
references: Med Care. 2003 May;41(5):582-92
references: 12719681
references: Expert Rev Hematol. 2011 Aug;4(4):399-406
references: 21801130
references: Am J Gastroenterol. 2008 May;103(5):1182-92
references: 18371137
references: Am J Hematol. 2010 Sep;85(9):650-4
references: 20661919
references: N Engl J Med. 2007 Jul 5;357(1):93-4
references: 17611217
references: Am J Kidney Dis. 2008 Nov;52(5):907-15
references: 18824288
references: J Nutr. 2001 Feb;131(2S-2):676S-688S; discussion 688S-690S
references: 11160598
references: J Appl Physiol (1985). 2000 Mar;88(3):1103-11
references: 10710409
references: Haematologica. 2008 Dec;93(12):1785-91
references: 18815191
references: World J Gastroenterol. 2007 Sep 28;13(36):4798-806
references: 17828809
references: J Am Soc Nephrol. 2008 Aug;19(8):1599-605
references: 18525001
references: Am J Hematol. 2011 Oct;86(10):860-2
references: 21922526
references: Nephrol Dial Transplant. 2004 Jun;19(6):1571-5
references: 15150356
references: Inflamm Bowel Dis. 2012 Mar;18(3):513-9
references: 21604328
references: Gut. 2004 Aug;53(8):1190-7
references: 15247190
references: Curr Med Res Opin. 2006 Apr;22(4):731-7
references: 16684434
references: Med Care. 1992 Jun;30(6):473-83
references: 1593914